In fact, a recent study found that prior treatment with pegylated-IFN-alfa-2b increased the effectiveness of adjuvant pembrolizumab (anti-PD-1 treatment) in patients with surgically removable advanced melanoma, although IRF1 and IRF2 status was not evaluated [34]. Here, IRF2 is linked to melanoma.